Susana V. P.
- Country
- Spain
- Department
- Hematology
Research Overview
- A Phase 1/2 Study of Enzomenib (DSP 5336) in Adults with Relapsed or Refractory Acute Leukemia, Including MLL-Rearranged or NPM1-Mutated Subtypes
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase 3 Study of Oral Arsenic Trioxide QTX-2101 in Newly Diagnosed Low-Risk Acute Promyelocytic Leukemia
Data & Insights
Has run more than one trial at 192 of 318 partner sites.
Specializations
Leukemia Research Focus
Specializes in investigating novel therapeutic approaches for acute myeloid leukemia (AML), with particular emphasis on treating both newly diagnosed and relapsed/refractory cases.
- FLT3-ITD mutation status in AML
- IDH1 mutation-positive AML
- Chronic Myelomonocytic Leukemia (CMML)
Conducts research on targeted therapies for specific genetic mutations in leukemia patients.
Therapeutic Innovation
Investigates cutting-edge treatment combinations involving novel inhibitors and established therapeutics for hematologic malignancies.
- FLT3, KIT and CSF1R inhibition
- Combination therapy approaches
- Maintenance treatment strategies
Explores innovative drug combinations with azacitidine and other therapeutic agents.
Hematologic Disorders
Extends research focus to include various myeloid disorders and their treatment approaches.
- Myelodysplastic Syndromes
- Myelodysplastic Neoplasms
- Treatment-resistant blood cancers
Addresses the needs of patients who are ineligible for intensive chemotherapy or have exhausted standard treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.